TRAILBLAZER-ALZ 2: A Phase 3 Study to Assess Safety and Efficacy of Donanemab in Early Symptomatic Alzheimer’s Disease (P18-3.005)

Thursday, April 7May 3, 2022Free AccessTRAILBLAZER-ALZ 2: A Phase 3 Study to Assess Safety and Efficacy of Donanemab in Early Symptomatic Alzheimer’s Disease (P18-3.005)Jennifer Zimmer, Paul Solomon, Cynthia D. Evans, Ming Lu, John R. Sims, Dawn A. Brooks, and Mark A. MintunAuthors Info & AffiliationsMay 3, 2022 issue98 (18_supplement)https://doi.org/10.1212/WNL.98.18_supplement.1688 Letters to the Editor